Cytokinetics Inc (NAS:CYTK)
$ 59.23 -0.91 (-1.51%) Market Cap: 6.21 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 41/100

Cytokinetics Inc at Needham Healthcare Conference Transcript

Apr 10, 2019 / 12:40PM GMT
Release Date Price: $8.72 (+2.23%)
Unidentified Analyst

Thank you, everyone, for attending the Needham Healthcare Conference.

It's my pleasure to introduce Robert Blum, President and CEO of Cytokinetics.

Robert Blum
Cytokinetics, Incorporated - President and CEO

Thank you to Needham for inviting Cytokinetics to provide this update. Thanks to you here in the room and those who may be listening in on the webcast. I'll be providing a corporate update for Cytokinetics over these next 25 or so minutes; and, in particular, talking about our pipeline of investigational medicines directed to diseases and conditions of severe muscle dysfunction and muscle weakness.

And we start our presentation with pictures of some of those patients who inspire us, who we know quite well, and personally who tour our labs and who provide feedback and guidance as to what will matter most to treating patients with these most severe, devastating diseases.

I'll be making some forward-looking statements. And I will refer you to our recent SEC filings, including our recent 10-K with regard to caveats to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot